Straits Times Index
3,344.76 +13.06 (+0.39%) Nikkei
39,341.54 -325.53 (-0.82%) Hang Seng
17,713.74 -376.19 (-2.08%) FTSE 100
8,221.44 -3.89 (-0.05%) Bitcoin USD
60,703.15 -1,027.80 (-1.66%) CMC Crypto 200
1,262.45 -3.69 (-0.29%)
XBIT Oct 2024 7.500 put
- GlobeNewswire
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen
- Simply Wall St.
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders
Key Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by...
- GlobeNewswire
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new fou
